1. EGFRMutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Author
-
Matthew Meyerson, Stacey Gabriel, Pasi A. Jänne, Jeffrey C. Lee, Hidefumini Sasaki, Neal I. Lindeman, Yoshitaka Fujii, J. Guillermo Paez, Bruce E. Johnson, Titus J. Boggon, William R. Sellers, Frederic J. Kaye, Michael J. Eck, Sean Tracy, Paula Herman, Katsuhiko Naoki, and Heidi Greulich
- Subjects
Male ,Lung Neoplasms ,Protein Conformation ,Amino Acid Motifs ,Molecular Sequence Data ,Mutation, Missense ,Antineoplastic Agents ,Adenocarcinoma ,EGFR Gene Mutation ,Gefitinib ,Japan ,Carcinoma, Non-Small-Cell Lung ,Cell Line, Tumor ,Humans ,Medicine ,EGFR Gene Amplification ,Amino Acid Sequence ,Epidermal growth factor receptor ,Enzyme Inhibitors ,Phosphorylation ,neoplasms ,EGFR Protein Overexpression ,Sequence Deletion ,EGFR inhibitors ,Multidisciplinary ,biology ,business.industry ,Genes, erbB-1 ,EGFR Tyrosine Kinase Inhibitor Therapy ,United States ,Protein Structure, Tertiary ,respiratory tract diseases ,ErbB Receptors ,Treatment Outcome ,Amino Acid Substitution ,Mutation ,Icotinib ,Quinazolines ,Cancer research ,biology.protein ,Female ,Controlled Clinical Trials as Topic ,business ,medicine.drug - Abstract
Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor geneEGFRwere found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.EGFRmutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest thatEGFRmutations may predict sensitivity to gefitinib.
- Published
- 2004
- Full Text
- View/download PDF